KPIs & Operating Metrics(New)
Growth Metrics

Amgen (AMGN) Net Cash Flow Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -50.54%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -45.98%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 54.26%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -44.49%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -50.46%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 29.14%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -32.34%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -26.50%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -50.46%
Dec 31, 2025 44.74%
Sep 30, 2025 -30.92%
Jun 30, 2025 16.12%
Mar 31, 2025 -29.36%
Dec 31, 2024 40.00%
Sep 30, 2024 -27.12%
Jun 30, 2024 -40.71%
Mar 31, 2024 -100.22%
Dec 31, 2023 -103.57%
Sep 30, 2023 118.98%
Jun 30, 2023 22.62%
Mar 31, 2023 143.87%
Dec 31, 2022 29.64%
Sep 30, 2022 -9.96%
Jun 30, 2022 10.25%
Mar 31, 2022 -76.92%
Dec 31, 2021 7.39%
Sep 30, 2021 43.02%
Jun 30, 2021 9.92%
Mar 31, 2021 -26.53%
Dec 31, 2020 -76.80%
Sep 30, 2020 -29.19%
Jun 30, 2020 58.74%
Mar 31, 2020 141.60%
Dec 31, 2019 -180.38%
Sep 30, 2019 90.28%
Jun 30, 2019 -90.29%
Mar 31, 2019 32.59%
Dec 31, 2018 -95.38%
Sep 30, 2018 73.33%
Jun 30, 2018 -25.18%
Mar 31, 2018 106.86%
Dec 31, 2017 145.60%
Sep 30, 2017 36.61%
Jun 30, 2017 -45.75%
Mar 31, 2017 44.09%
Dec 31, 2016 62.08%
Sep 30, 2016 -29.83%
Jun 30, 2016 -27.67%
Mar 31, 2016 -19.74%
Dec 31, 2015 33.10%
Sep 30, 2015 -179.71%
Jun 30, 2015 -17.23%
Mar 31, 2015 31.85%
Dec 31, 2014 -73.95%
Sep 30, 2014 31.58%
Jun 30, 2014 -48.01%
Mar 31, 2014 61.21%
Dec 31, 2013 -148.37%
Sep 30, 2013 25.94%
Jun 30, 2013 99.28%
Mar 31, 2013 -5.56%
Dec 31, 2012 -54.71%
Sep 30, 2012 -26.88%
Jun 30, 2012 104.86%
Mar 31, 2012 -67.87%